Key result
Coronary artery bypass grafting significantly reduced the long-term risk of all-cause mortality (HR 0.63) compared to medical therapy in patients with chronic total occlusion and left ventricular systolic dysfunction.
Why the study?
The optimal treatment strategy for patients with coronary chronic total occlusion and left ventricular systolic dysfunction remains unclear.
Does CTO revascularization (PCI or CABG) improve long-term survival in patients with chronic total occlusion and left ventricular systolic dysfunction compared with medical therapy?
Cohort (n=987)
No
Does CTO revascularization (PCI or CABG) improve long-term survival in patients with chronic total occlusion and left ventricular systolic dysfunction compared with medical therapy?
Answers are grounded in this paper and cite their sources.
Substantial long-term mortality in CTO with LV dysfunction; observational data leave optimal strategy open for randomized trials.
BACKGROUND: The optimal treatment strategy for patients with coronary chronic total occlusion (CTO) and left ventricular systolic dysfunction (LVSD) remains unclear. This study investigated the long-term outcomes of percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and medical therapy (MT) in this specific patient cohort. METHODS AND RESULTS: This retrospective cohort study included 987 consecutive patients with CTO and LVSD who met the inclusion criteria and underwent either CTO-PCI (n=277), CTO-CABG (n=222), or CTO-MT (n=488) between 2014 and 2020. The primary outcome was all-cause mortality during follow-up. Secondary endpoints were major adverse cardiac and cerebrovascular events (MACCE) and their components, including cardiovascular mortality, myocardial infarction (MI), stroke, unplanned revascularization, and hospitalization for heart failure. During a median follow-up of 5.3 years, 232 (23.51%) patients died from any cause. In the unadjusted analysis, CTO-MT was associated with worse long-term survival prospects. After inverse probability of treatment weighting and variable adjustment, CTO-PCI and CTO-CABG demonstrated significant reductions in the long-term risks of all-cause and cardiovascular mortality. Notably, CTO-CABG was associated with the lowest long-term risks of MACCE, MI, unplanned revascularization, and hospitalization for heart failure. CONCLUSIONS: For patients with CTO and LVSD, successful CTO revascularization significantly improved long-term survival compared with CTO-MT. CTO-CABG can be regarded as the optimal treatment modality for better long-term prognosis.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2024) conducted a cohort in Chronic total occlusion and left ventricular systolic dysfunction (n=987). Coronary artery bypass grafting (CTO-CABG) vs. Medical therapy (CTO-MT) was evaluated on All-cause mortality (HR 0.63, 95% CI 0.50-0.79, p=<0.001). Coronary artery bypass grafting significantly reduced the long-term risk of all-cause mortality (HR 0.63) compared to medical therapy in patients with chronic total occlusion and left ventricular systolic dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: